Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.

Neurology - 8 May 2007

Fleisher A S, Sowell B B, Taylor C, Gamst A C, Petersen R C, Thal L J

Abstract excerpt

OBJECTIVE: To investigate the neurocognitive measures that best predict progression from amnestic mild cognitive impairment (aMCI) to Alzheimer disease (AD). METHODS: We evaluated 539 participants with aMCI from the Alzheimer's Disease Cooperative Study clinical drug trial of donepezil, vitamin E, or placebo. During the study period of 36 months, 212 aMCI participants progressed to AD. Using progression from aMCI...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Distribution
Share to Antioxidants
Share to Cholinesterase Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cognition Disorders

Share to Indans

Share to Piperidines

Share to Sex Distribution

Share to Vitamin E

Source

Identifiers

PMID: 17287448
DOI: 10.1212/01.wnl.0000258542.58725.4c

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.PMID 17287448Read ↗

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.Semantic proximity Read ↗

Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.Semantic proximity Read ↗

Predicting Progression & Cognitive Decline in Amyloid-Positive Patients with Alzheimer's DiseaseSemantic proximity Read ↗

Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study.Semantic proximity Read ↗

Neuropsychological measures in normal individuals that predict subsequent cognitive decline.Semantic proximity Read ↗

Machine Learning Predicts Conversion from Normal Aging to Mild Cognitive Impairment Using Medical History, APOE Genotype, and Neuropsychological Assessment.Semantic proximity Read ↗

Predicting conversion to Alzheimer’s Disease in individuals with Mild Cognitive Impairment using clinically transferable featuresSemantic proximity Read ↗

Standardized Comparison of Clinical, Cognitive, Genetic, Neuroimaging, and Fluid Biomarkers for Predicting 24-Month Progression from Mild Cognitive Impairment to Alzheimer’s DiseaseSemantic proximity Read ↗

Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.Semantic proximity Read ↗

A practical method to predict rate of cognitive decline in mild to moderate Alzheimer's disease.Semantic proximity Read ↗

An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM.Semantic proximity Read ↗

Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.